MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC

MAIA Biotechnology, Inc.

Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.
Data from THIO-101 trial: Ateganosine + ICI in relapsed NSCLC patients.
Poster title indicates sustained response and long-term therapeutic benefits after treatment cessation.
No financial or numerical efficacy data disclosed in the 8-K; poster available on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.